Loading...
Loading...
ATRA| Name | Value |
|---|---|
| Revenues | 40.2M |
| Cost of Revenue | 7.6M |
| Gross Profit | 32.6M |
| Operating Expense | 54.3M |
| Operating I/L | -21.8M |
| Other Income/Expense | -0.2M |
| Interest Income | 0.5M |
| Pretax | -21.9M |
| Income Tax Expense | -0.0M |
| Net Income/Loss | -21.9M |
Atara Biotherapeutics, Inc. is a T-cell immunotherapy company focused on developing off-the-shelf treatments for cancer, autoimmune, and viral diseases. The company's lead product, tabelecleucel, is in Phase 3 clinical trials for treating epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, hematologic and solid tumors, including nasopharyngeal carcinoma. Atara is also developing next-generation CAR T immunotherapies for hematologic malignancies and solid tumors, such as ATA2271, ATA3271 for mesothelin, ATA2431, ATA3219 for B-cell malignancies, and ATA188 for multiple sclerosis. Additionally, the company has a program, ATA368, targeting human papillomavirus associated cancers.
